Antiretroviral drug susceptibility of a hinge region variant of HIV-1 subtype C protease

Simple item page
dc.contributor.authorZondagh, Jake
dc.date.accessioned2018-10-31T12:47:25Z
dc.date.available2018-10-31T12:47:25Z
dc.date.issued2018
dc.descriptionA thesis submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg in fulfilment of the requirements for the degree of Doctor of Philosophy. Johannesburg, 28 May 2018.
dc.description.abstractSince their discovery, protease inhibitors continue to be an essential component of antiretroviral treatment for human immunodeficiency virus type 1 (HIV-1). However, the development of resistance to protease inhibitors remains one of the most significant challenges in the fight for sustained viral suppression in those infected with HIV-1. Studies show that specific mutations arising within the HIV-1 gag and protease genes can lead to the development of resistance. In this research, a South African HIV-1 subtype C Gag-protease variant (W1201i) was investigated. This variant was considered due to the presence of a mutation and insertion (N37T↑V), located within the hinge region of the protease enzyme. Moreover, the variant displayed the following polymorphisms: Q7K, I13V, G16E, M36T, D60E, Q61E, I62V and M89L. Genotyping of W1201i Gag revealed a previously unreported MSQAG insertion between the CA/p2 and p2/NC cleavage sites. Additionally, a mutation and insertion (I372L↑M), and multiple polymorphisms (S369N, S371N, I373M and G377S) were discovered within the p2/NC cleavage site. Single-cycle phenotypic assays were performed to determine the drug susceptibility and replication capacity of the variant. The results show that the mutations present in the N37T↑V protease conferred a replicative advantage and reduced susceptibility to lopinavir, atazanavir and darunavir. Interestingly, the mutations in W1201i Gag were found to modulate both replication capacity and protease inhibitor susceptibility. In silico studies were performed to understand the physical basis for the observed variations. Molecular dynamics simulations showed that the N37T↑V protease displayed altered dynamics around the hinge and flap region and highlighted the amino acids responsible for the observed fluctuations. Furthermore, induced fit docking experiments showed that the variant bound the iv protease inhibitors with fewer favourable chemical interactions than the wild-type protease. Collectively, these data elucidate the biophysical basis for the selection of hinge region mutations and insertions by the HI virus and show that protease, as well as Gag, needs to be evaluated during resistance testing.en_ZA
dc.description.librarianEM2018en_ZA
dc.format.extentOnline resource (139 leaves)
dc.identifier.citationZondagh, Jake (2018) Antiretroviral drug susceptibility of a hinge region variant of HIV-1 subtype C protease, University of the Witwatersrand, Johannesburg, <http://hdl.handle.net/10539/25929>
dc.identifier.urihttps://hdl.handle.net/10539/25929
dc.language.isoenen_ZA
dc.subject.lcshAntiretroviral agents
dc.subject.lcshAIDS (Disease)--Treatment--South Africa
dc.subject.lcshHIV infections--Treatment--South Africa
dc.subject.lcshProtease inhibitors
dc.titleAntiretroviral drug susceptibility of a hinge region variant of HIV-1 subtype C proteaseen_ZA
dc.typeThesisen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Zondagh_336484_PhD_Final_Submission.pdf
Size:
6.92 MB
Format:
Adobe Portable Document Format
Description:
Main Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
ETD Collection